Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering
Rhea-AI Summary
Coeptis Therapeutics has secured $4.3 million from a Series A Preferred offering led by CJC Investment Trust, helmed by board member Christopher Calise. The Series A Preferred stock is convertible to common stock at $0.40 per share, with investors gaining a 6.45% equity interest in SNAP Biosciences and GEAR Therapeutics, new subsidiaries of Coeptis. Proceeds will repay outstanding obligations, support working capital, and fund general corporate purposes. CEO Dave Mehalick highlighted the financing's timing, aligning with anticipated significant milestones and strengthening the company's balance sheet and growth prospects.
Positive
- Secured $4.3 million from Series A Preferred offering.
- Financing led by board member, indicating strong internal support.
- Series A Preferred stock price is at a premium of $0.40 per share.
- Investors receive a 6.45% equity interest in new subsidiaries SNAP Biosciences and GEAR Therapeutics.
- Funding strengthens balance sheet and supports innovative cell therapy platforms.
Negative
- Funds used partially for repayment of outstanding obligations, indicating existing liabilities.
News Market Reaction – COEP
On the day this news was published, COEP declined 8.81%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Bolsters Company's Corporate Mission
Financing Led by Board Member and Priced at Premium to Market Price
Under the terms of the financing, the Series A Preferred is convertible into shares of the Company's common stock at a price of
Dave Mehalick, President and CEO of Coeptis Therapeutics said, "We are grateful for the continued support from our investors, particularly in these transformative times for Coeptis Therapeutics. These individuals share our passion and long-term vision for Coeptis, and their support goes beyond investment, reflecting a focus on the Company's future."
"This financing comes at an opportune moment as we are anticipating several significant near-term milestones. The commitment from our investors not only strengthens our balance sheet but also bolsters our innovative cell therapy platforms and long-term growth prospects."
Proceeds from this financing will be allocated towards repayment of outstanding obligations, working capital, and general corporate purposes.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the
Contacts
Coeptis Therapeutics, Inc.
IR@coeptistx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-closes-on-4-3-million-of-series-a-preferred-offering-302177491.html
SOURCE Coeptis Therapeutics
FAQ
What recent financing did Coeptis Therapeutics (COEP) secure?
At what price is the Series A Preferred stock convertible for Coeptis Therapeutics (COEP)?
Who led the recent financing round for Coeptis Therapeutics (COEP)?
What equity interest did investors receive in Coeptis Therapeutics' new subsidiaries?
How will Coeptis Therapeutics (COEP) use the proceeds from the recent financing?
